{
  "id": "CD016136",
  "draft": "Is intravenous iron (given through a vein) better than oral iron (taken by mouth) for treating iron deficiency anemia in pregnant women?\n\nKey Messages\n- In pregnant women with iron deficiency anemia, intravenous iron likely slightly increases hemoglobin levels and reduces anemia compared to oral iron.\n- The current evidence does not clearly show whether intravenous iron increases or decreases the risk of unwanted effects such as severe infections, prolonged hospital stays, or admissions to intensive care units, and more research is needed to understand its safety and effectiveness fully.\n- Future studies should investigate the long-term effects of intravenous versus oral iron, focus on outcomes that are important to patients and healthcare providers, such as the impact on maternal and infant health, and improve the reporting of adverse events to provide clearer guidance for treating iron deficiency anemia in pregnancy.\n\nWhat is iron deficiency anemia in pregnancy?\nIron deficiency anemia is a condition where the body does not have enough iron to produce adequate amounts of hemoglobin, a substance in red blood cells that carries oxygen to different parts of the body. In pregnancy, iron deficiency anemia can occur due to the increased demand for iron to support the growth of the baby. If not treated, iron deficiency anemia can cause serious health problems for both the mother and the baby. These can include heavy bleeding after birth (postpartum hemorrhage or PPH), needing a blood transfusion, and the baby having a low birth weight.\n\nWhat are the common treatments for iron deficiency anemia in pregnancy?\nThe common treatments for iron deficiency anemia in pregnancy are oral iron supplements, such as ferrous sulfate, ferrous fumarate, and ferrous gluconate, and intravenous iron preparations, such as iron sucrose, ferric carboxymaltose, ferric derisomaltose, and ferumoxytol. Oral iron supplements are typically the first line of treatment, but intravenous iron preparations may be used in cases where oral iron is not effective or tolerated.\n\nWhat did the review authors want to find out?\nThe review authors wanted to evaluate the effect and safety of intravenous iron compared to oral iron for treating iron deficiency anemia in pregnancy. They aimed to find out whether intravenous iron is more effective than oral iron in increasing hemoglobin levels, reducing anemia, and improving pregnancy outcomes, such as postpartum hemorrhage and the need for blood transfusion. They also wanted to assess the safety of intravenous iron and its potential to cause adverse events, such as maternal mortality and morbidity.\n\nWhat methods did the researchers use?\nWe searched for studies comparing intravenous iron to oral iron for treating iron deficiency anemia in pregnancy, summarized their results, and rated our confidence in the evidence.\n\nWhat did the researchers find?\nWe found 13 studies that involved 3939 people with iron deficiency anemia in pregnancy. Researchers mainly conducted the studies in India and Africa. The gestational age at baseline ranged from 13 to 37 weeks, and hemoglobin levels ranged from 5.0 to just below 11.0 g/dL. The most frequently compared preparations were intravenous iron sucrose versus oral ferrous sulfate. Most RCTs were at low risk of bias. This Cochrane Review was partially funded by the WHO and was supported by the UK Medical Research Council funding. Intravenous iron probably slightly increases hemoglobin levels and reduces anemia in pregnancy compared to oral iron. Hemoglobin levels after birth may be slightly increased with intravenous iron, but the effect on severe anemia after birth is very uncertain. Intravenous iron may make little to no difference in the risk of serious bleeding after birth, and blood transfusion rates are probably unaffected by the route of administration. Intravenous iron may cause little to no difference in maternal health, but the evidence is limited.\n\nWhat are the limitations of the evidence?\nThe evidence is limited by differences in the people studied and how the treatments were given, very small study sizes, possible lack of blinding (participants knew which treatment they received), and poor reporting of results.\n\nIs the evidence up to date?\nThe evidence is up to date to March 2024.\n\nHow can the evidence be improved?\nFuture studies should investigate the long-term effects of intravenous versus oral iron, focus on outcomes that are important to patients and healthcare providers, such as the impact on maternal and infant health, and improve the reporting of adverse events to provide clearer guidance for treating iron deficiency anemia in pregnancy.",
  "metrics": [
    {
      "linguistic_evaluation": {
        "words": {
          "value": 748,
          "rating": "within_limit",
          "direction": null,
          "feedback": null
        },
        "sentences": {
          "value": 33,
          "rating": "info",
          "direction": null,
          "feedback": null
        },
        "words_per_sentence": {
          "value": 22.666666666666668,
          "rating": "P75",
          "direction": "lower_better",
          "feedback": null
        },
        "passive_voice": {
          "value": 18,
          "rating": "P75",
          "direction": "lower_better",
          "feedback": null
        },
        "active_voice": {
          "value": 55,
          "rating": "P75",
          "direction": "higher_better",
          "feedback": null
        },
        "pronouns": {
          "value": 20,
          "rating": "P50",
          "direction": "higher_better",
          "feedback": null
        },
        "nominalization": {
          "value": 18,
          "rating": "P75",
          "direction": "lower_better",
          "feedback": null
        },
        "nouns": {
          "value": 248,
          "rating": "BEYOND_P90",
          "direction": "lower_better",
          "feedback": "Deviates from typical PLS patterns. Consider reducing from 248.0 to <116.0 (median)"
        },
        "flesch_reading_ease": {
          "value": 33.629402852049935,
          "rating": "P25",
          "direction": "higher_better",
          "feedback": null
        },
        "flesch_kincaid_grade": {
          "value": 14.199732620320855,
          "rating": "P75",
          "direction": "lower_better",
          "feedback": null
        },
        "automated_readability_index": {
          "value": 14.007450980392157,
          "rating": "P75",
          "direction": "lower_better",
          "feedback": null
        },
        "coleman_liau_index": {
          "value": 12.985882352941175,
          "rating": "P75",
          "direction": "lower_better",
          "feedback": null
        },
        "gunning_fog_index": {
          "value": 18.157575757575756,
          "rating": "P75",
          "direction": "lower_better",
          "feedback": null
        },
        "lix": {
          "value": 53.14795008912656,
          "rating": "P50",
          "direction": "lower_better",
          "feedback": null
        },
        "rix": {
          "value": 6.909090909090909,
          "rating": "P50",
          "direction": "lower_better",
          "feedback": null
        },
        "smog_index": {
          "value": 16.152946437965905,
          "rating": "BEYOND_P90",
          "direction": "lower_better",
          "feedback": "Deviates from typical PLS patterns. Consider reducing from 16.2 to <12.1 (median)"
        },
        "dale_chall_readability": {
          "value": 7.837127629233512,
          "rating": "P75",
          "direction": "lower_better",
          "feedback": null
        },
        "complex_words_dc": {
          "value": 318,
          "rating": "BEYOND_P90",
          "direction": "lower_better",
          "feedback": "Deviates from typical PLS patterns. Consider reducing from 318.0 to <160.0 (median)"
        },
        "complex_words": {
          "value": 170,
          "rating": "BEYOND_P90",
          "direction": "lower_better",
          "feedback": "Deviates from typical PLS patterns. Consider reducing from 170.0 to <84.0 (median)"
        },
        "long_words": {
          "value": 228,
          "rating": "BEYOND_P90",
          "direction": "lower_better",
          "feedback": "Deviates from typical PLS patterns. Consider reducing from 228.0 to <122.0 (median)"
        }
      },
      "word_count_status": {
        "word_count": 748,
        "limit": 850,
        "status": "within_limit",
        "message": "Word count: 748 ✓ WITHIN LIMIT (≤850 words)"
      },
      "summary": {
        "P25_count": 1,
        "P50_count": 3,
        "P75_count": 9,
        "P90_count": 0,
        "P10_count": 0,
        "BEYOND_P90_count": 5,
        "BELOW_P10_count": 0,
        "total_evaluated": 18,
        "P25_percentage": 5.555555555555555,
        "P50_percentage": 16.666666666666664,
        "P75_percentage": 50,
        "P90_percentage": 0,
        "P10_percentage": 0,
        "BEYOND_P90_percentage": 27.77777777777778,
        "BELOW_P10_percentage": 0,
        "best_quartile_rate": 55.55555555555556,
        "overall_assessment": "GOOD CONFORMITY WITH PLS PATTERNS"
      }
    }
  ],
  "evaluation": [
    {
      "grade": "NOT_APPROVED",
      "feedback": "Thank you for this draft. All the required sections are present, the facts are accurate, and the word count is within the limit. However, the summary is not yet ready for publication as it contains several clarity and structural issues that make it difficult for a lay audience to understand. I've outlined the 3 most important improvements below.\n\n### Top 3 Improvements Needed\n\n**1. Replace technical jargon and long lists of drug names with simpler terms.**\n\nThe draft includes many technical terms and specific drug names that are unnecessary for a plain language summary and can intimidate readers.\n\n*   **Problematic text:** \"The common treatments for iron deficiency anemia in pregnancy are oral iron supplements, such as ferrous sulfate, ferrous fumarate, and ferrous gluconate, and intravenous iron preparations, such as iron sucrose, ferric carboxymaltose, ferric derisomaltose, and ferumoxytol.\"\n*   **Why it's an issue:** This long list of chemical names is overwhelming and doesn't add to the reader's understanding of the core comparison between oral and intravenous iron.\n*   **Suggested rewrite:** \"Common treatments include iron supplements taken by mouth (oral iron) or given through a vein (intravenous iron).\"\n\n*   **Problematic text:** \"...assess the safety of intravenous iron and its potential to cause adverse events, such as maternal mortality and morbidity.\"\n*   **Why it's an issue:** \"Adverse events,\" \"mortality,\" and \"morbidity\" are clinical terms. Simpler, more direct language is better.\n*   **Suggested rewrite:** \"...check for unwanted effects, such as serious health problems or death for the mother.\"\n\n**2. Break up long, complex sentences.**\n\nSome sentences are very long and contain multiple ideas, making them hard to follow. This is especially true for the final key message, which is repeated later in the text.\n\n*   **Problematic text:** \"Future studies should investigate the long-term effects of intravenous versus oral iron, focus on outcomes that are important to patients and healthcare providers, such as the impact on maternal and infant health, and improve the reporting of adverse events to provide clearer guidance for treating iron deficiency anemia in pregnancy.\"\n*   **Why it's an issue:** This 49-word sentence lists three distinct recommendations, which get lost in a single block of text.\n*   **Suggested rewrite:** \"Future research should:\\n- Look at the long-term effects of both treatments.\\n- Focus on results that matter most to mothers and babies.\\n- Clearly report any unwanted effects to help guide future treatment.\"\n\n**3. Improve the structure by removing redundancy and relocating misplaced information.**\n\nThe summary's structure can be confusing due to repeated sections and oddly placed information.\n\n*   **Problematic structure 1:** The funding statement (\"This Cochrane Review was partially funded by the WHO...\") is placed in the middle of the results section.\n*   **Why it's an issue:** This interrupts the flow of the findings. Information on funding should be separate from the clinical results.\n*   **Suggested fix:** Move the funding sentence to the very end of the summary, possibly under its own subheading like \"Funding\".\n\n*   **Problematic structure 2:** The third key message is repeated verbatim as the final section, \"How can the evidence be improved?\"\n*   **Why it's an issue:** This is redundant. The point is already made in the key messages at the top.\n*   **Suggested fix:** Remove the final section (\"How can the evidence be improved?\") entirely.",
      "pls_evaluation_summary": "The linguistic analysis shows that while the summary's length and sentence structure are mostly within typical ranges, its vocabulary is significantly more complex than a standard Plain Language Summary. Five key metrics—`nouns`, `smog_index`, `complex_words_dc`, `complex_words`, and `long_words`—are in the 'BEYOND_P90' category. This indicates the text relies too heavily on technical, multi-syllable, and noun-based language, which supports the editorial recommendation to simplify terminology and sentence structure to improve readability for a lay audience."
    }
  ]
}